The Interferon-inducible NAMPT acts as a protein phosphoribosylase to restrict viral infection

Zhang S, Xie N, Liu Y, Qin C, Savas AC, Wang TY, et al. | bioRxiv | 2023 | Evidence: limited

Plain-language summary

Published 2023 in bioRxiv, this work by Zhang S and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

Mechanistic study in bioRxiv (2023) on NAD+/sirtuin/longevity biology
Adds to the foundational literature underlying NMN supplementation rationale
First author: Zhang S

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

← Back to research index